Analyzing brain wave patterns to find new uses for existing drugs in rare diseases
Official title: EEG Signature Analysis for Drug Repurposing for Rare Diseases
Funded at Psychogenics, INC. · NIH-11004734 · Data updated 2026-11-12
This study is looking to find new ways to use existing medications for rare diseases and mental health conditions by analyzing brain wave patterns from animal models, making it easier and cheaper to discover helpful treatments for people like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Psychogenics, INC. NIH-funded |
| Lab location | 1 site (Paramus, UNITED STATES) |
| Project start | August 5, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $560,641 |
| NIH project number | 1R44MH138151-01 |
| Project ID | NIH-11004734 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with rare diseases or psychiatric disorders who may benefit from new treatment options.
✕Less likely to help
Patients with common diseases or those who do not have access to EEG testing may not receive benefits from this research.
What this research studies
This research focuses on improving drug discovery for rare diseases and psychiatric disorders by utilizing EEG (electroencephalogram) data. The team will develop a platform that analyzes brain wave patterns from animal models of rare diseases to identify potential new uses for existing drugs. By comparing these patterns with a database of known drug signatures, the researchers aim to generate hypotheses for drug repurposing. This approach seeks to reduce the high costs and risks associated with traditional drug development.
Why it matters
Potential benefit: If successful, this research could lead to faster and more cost-effective treatments for patients with rare diseases.
How similar studies have gone: Previous research has shown promise in drug repurposing using similar algorithmic approaches, indicating potential for success in this novel application.
Where this research is happening
-
Psychogenics, INC.
Paramus, United States Active
Researchers
- Principal investigator: Brunner, Daniela — Psychogenics, INC.
- Study coordinator: Brunner, Daniela
Related research
Other NIH-funded projects on the same topics.
-
Liver pathobiology from rare liver diseases
A study at UCSF looks at why rare liver conditions cause liver damage, with the aim of finding new ways to diagnose and treat chronic liver disease.
-
Data Management and Coordinating Center support for Rare Diseases Research
A national rare diseases research program is funding a center to manage data and coordinate studies to help improve diagnosis, care, and potential treatments for children with rare conditions.
-
EEG-based drug repurposing for rare CNS diseases
A new approach uses EEG brain signatures to find existing drugs that might help people with rare nervous-system disorders.
-
Ethics of Engaging Patient Groups in Drug Development for Rare Diseases
This grant asks how patient and family groups can ethically help shape rare-disease drug development from idea to market, with input from patients, families, doctors, and researchers.
-
Center for Polyamine Disorders group study of rare metabolic disorders
A research consortium is studying a group of rare metabolic disorders linked to polyamines and aims to understand symptoms, biomarkers, and disease progression to improve care.
-
Encore: speeding up finding new uses for existing drugs to help kids with rare diseases
A big NIH project will test thousands of existing medicines to see if any can help treat rare genetic diseases in children.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.